Antihypertensive efficacy and safety of Candesartan/HCT 32/25 mg in comparison with individual components and placebo

Study identifier:D2456C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) 32 mg and Hydrochlorothiazide (HCT) 25 mg compared with CC 32 mg, HCT 25 mg and Placebo in Hypertensive Adults

Medical condition

hypertension

Phase

Phase 3

Healthy volunteers

Study drug

Candesartan cilexetil, Hydrochlorothiazide, Candesartan/HCT 32/25 mg

Sex

All

Actual Enrollment

2207

Study type

Interventional

Age

20 Years - 80 Years

Date

Study Start Date: 01 Jan 2007

Primary Completion Date: 01 Jan 2008

Study Completion Date: 01 Jan 2008

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2010 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

- Patients will be eligible for enrolment into the study (Visit 1) if they fulfil all of the following criteria:
- Provision of signed Informed Consent
- Primary hypertension, untreated or treated with a maximum of 2 antihypertensive drugs (substances), which the patient and the physician are willing to withdraw at enrolment and replace with placebo.
- Mean sitting DBP 90-114 mmHg (value calculated in the eCRF) at Visits 1 and 2
- Patients will be eligible for randomisation (Visit 4) if they fulfil the following criterion:
- Mean sitting DBP of 90-114 mmHg (value calculated in the eCRF) at the end of the 4-week single-blind placebo run-in period. The run-in period should not be shorter than 4 weeks.

Exclusion Criteria

- Pregnant or lactating women, or women of childbearing potential not practising an adequate method of contraception eg, intrauterine device, oral contraception or progesterone implant. Pregnancy must be excluded by a negative pregnancy test at Visit 1.
- Secondary or malignant hypertension
- Sitting SBP of 180 mmHg or more
- Myocardial infarction, stroke, coronary bypass surgery or transient ischaemic attack within 6 months before enrolment
- Angina pectoris requiring more treatment than short-acting nitrates
- Chronic use of NSAIDs
- Aortic or mitral valve stenosis
- Cardiac failure requiring treatment
- Cardiac arrhythmia requiring treatment
- Gout
- Renal artery stenosis or kidney transplantation
- Intravascular volume depletion
- Hypersensitivity to any component of the investigational products or to any sulphonamide derived drugs
- Concomitant disease which may interfere with the assessment of the patient
- Past or present alcohol or drug abuse, or any condition associated with poor compliance that in the opinion of the investigator might affect the patient’s participation in the study
- Chronic liver disease
- Concomitant or previous treatment with any other investigational drug within 20 days of enrolment
- Previous enrolment in the present study

No locations available

Arms	Assigned Interventions
No Intervention: 4 Placebo	-
Active Comparator: 2 Candesartan cilexetil	Drug: Candesartan cilexetil 32 mg oral tablet Other Name: ATACAND
Active Comparator: 3 Hydrochlorothiazide (HCT)	Drug: Hydrochlorothiazide 25 mg oral tablet Other Name: HCTZ
Experimental: 1 Candesartan cilexetil + Hydrochlorothiazide Combination	Drug: Candesartan cilexetil 32 mg oral tablet Other Name: ATACAND Drug: Hydrochlorothiazide 25 mg oral tablet Other Name: HCTZ

Documents available

AstraZeneca Clinical Trial Information – Outside US
Download
https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=309&filename=CSR-D2456C00002.pdf
Download
CSR-D2456C00002.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

[email protected]

Investigators

Principal Investigator

Michael Klibaner

AstraZeneca